Wave Life Sciences, Inc.
- WVE · Nasdaq
- Pharmaceutical Preparations
- Cambridge, MA
- 317 employees
- CIK 0001631574
Updated from SEC filings through
Top things to know
Executives
- Paul Bolno MD, MBA, President and Chief Executive Officer at Wave Life Sciences 8-K, 2026-10-27
- Paul B. Bolno President and Chief Executive Officer 10-K, 2026-02-26
- Kyle Moran Chief Financial Officer 10-K, 2026-02-26
- Erik Ingelsson Chief Scientific Officer 3, 2026-04-17
- Christopher I. Wright Chief Medical Officer 3, 2026-04-17
- Chandra Vargeese Chief Technology Officer , Head of Platform Discovery Sciences 10-K, 2026-02-26
What leadership is saying
“We continue to make notable progress advancing our lead clinical programs. Following positive FDA feedback, planning is underway for our potentially registrational trial of WVE-006 for AATD, which we believe offers an efficient path to potential full and accelerated approval, without the need for a separate confirmatory trial. Our growing body of clinical data support WVE-006’s potential to offer a new standard of care for individuals living with AATD”
Earnings press release (8-K Ex. 99.1), filed October 27, 2026
Wave Life Sciences, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Cambridge, MA. It trades as WVE on Nasdaq. Revenue was $42.7M in the fiscal year ending December 31, 2025, -60.5% from the year before. It reported about 317 employees. Paul Bolno is MD, MBA, President and Chief Executive Officer at Wave Life Sciences.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $42.7M 10-K, 2026-02-26 | $108M 10-K, 2026-02-26 | $113M 10-K, 2026-02-26 | $3.6M 10-K, 2025-03-04 | $41.0M 10-K, 2023-03-23 |
| Operating income | -$215M 10-K, 2026-02-26 | -$110M 10-K, 2026-02-26 | -$68.0M 10-K, 2026-02-26 | -$163M 10-K, 2025-03-04 | -$127M 10-K, 2023-03-23 |
| SG&A | $75.3M 10-K, 2026-02-26 | $59.0M 10-K, 2026-02-26 | $51.3M 10-K, 2026-02-26 | $50.5M 10-K, 2025-03-04 | $46.1M 10-K, 2023-03-23 |
| Net income | -$204M 10-K, 2026-02-26 | -$97.0M 10-K, 2026-02-26 | -$57.5M 10-K, 2026-02-26 | -$162M 10-K, 2025-03-04 | -$122M 10-K, 2023-03-23 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Paul Bolno | MD, MBA, President and Chief Executive Officer at Wave Life Sciences | 8-K, 2026-10-27 |
| Paul B. Bolno | President and Chief Executive Officer | 10-K, 2026-02-26 |
| Kyle Moran, CFA | Named in proxy bio: Chief Financial Officer | DEF 14A, 2026-10-14 |
| Kyle Moran Chief Financial Officer at Wave Life Sciences | Chief Financial Officer | 10-K, 2026-02-26 |
| Chris Wright, M.D, Ph.D. | Named in proxy bio: Chief Medical Officer | DEF 14A, 2026-10-14 |
| Erik Ingelsson Chief Scientific Officer at Wave Life Sciences | Chief Scientific Officer | 3, 2026-04-17 |
| Christopher I. Wright | Chief Medical Officer | 3, 2026-04-17 |
| Chandra Vargeese | Chief Technology Officer , Head of Platform Discovery Sciences | 10-K, 2026-02-26 |
| Christopher Francis | Senior Vice President , Corporate Development, Head of Emerging Areas | 10-K, 2026-02-26 |
| Christian Henry | Chairman of the Board of Directors | 10-K, 2026-02-26 |
| Adrian Rawcliffe | Director | 10-K, 2026-02-26 |
| Aik-Na Tan | Director | 10-K, 2026-02-26 |
| Gregory L. Verdine, Ph.D. | Director | 10-K, 2026-02-26 |
| Heidi L. Wagner | Director | 10-K, 2026-02-26 |
| Ken Takanashi | Director | 10-K, 2026-02-26 |
| Mark H. N. Corrigan, M.D. | Director | 10-K, 2026-02-26 |
What Wave Life Sciences, Inc. does
We are a clinical-stage biotechnology company focused on unlocking the broad potential of ribonucleic acid (“RNA”) medicines (also known as oligonucleotides), or those targeting RNA, to transform human health. Our RNA medicines platform, PRISM ® , combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 197.2 million (as of October 21, 2026) | 10-Q, October 27, 2026 |
|---|---|---|
| Public float | $851M (as of June 30, 2025) | 10-K/A, April 30, 2026 |
| Reportable segments | 1 (period ending June 30, 2026) | 10-Q, July 30, 2026 |
| Latest proxy statement | Meeting November 12, 2026 (filed October 14, 2026) | DEF 14A, October 14, 2026 |
| Auditor | Kpmg LLP (Boston, Massachusetts) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| August 12, 2026 | Adrian Rawcliffe Director | Sale | 12,700 | $67K | Form 4, August 13, 2026 |
| August 11, 2026 | Heidi L. Wagner Director | Sale | 7,000 | $42K | Form 4, August 13, 2026 |
| August 11, 2026 | Ken Takanashi Director | Sale | 3,864 | $23K | Form 4, August 13, 2026 |
| August 11, 2026 | Aik Na Tan Director | Sale | 432 | $3K | Form 4, August 13, 2026 |
| March 30, 2026 | Capital Healthcare Fund LP RA Director | Buy | 8,772,496 | $54.6M | Form 4, March 30, 2026 |
| March 30, 2026 | Capital Management L.P. Ra Director | Buy | 8,772,496 | $54.6M | Form 4, March 30, 2026 |
| March 30, 2026 | Peter Kolchinsky Director | Buy | 8,772,496 | $54.6M | Form 4, March 30, 2026 |
| March 30, 2026 | Rajeev M. Shah Director | Buy | 8,772,496 | $54.6M | Form 4, March 30, 2026 |
Recent 8-K events
- 8-K filed 2026-10-27
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-30
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-26
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-18
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-04-28
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-04-21
- Item 8.01 Other events
- 8-K filed 2026-04-15
- Item 1.01 Entry into a material definitive agreement
- Item 8.01 Other events
- 8-K filed 2026-03-26
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-02-26
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-02-02
- Item 8.01 Other events
Frequently asked questions about Wave Life Sciences, Inc.
- What does Wave Life Sciences, Inc. do?
- In its own words, from Item 1 of its 10-K: "We are a clinical-stage biotechnology company focused on unlocking the broad potential of ribonucleic acid (“RNA”) medicines (also known as oligonucleotides), or those targeting RNA, to transform human health. Our RNA medicines platform, PRISM ® , combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders."
- What is Wave Life Sciences, Inc.'s revenue?
- $42.7M for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
- Is Wave Life Sciences, Inc. profitable?
- Wave Life Sciences, Inc. reported net income of -$204M for the fiscal year ending December 31, 2025.
- How many employees does Wave Life Sciences, Inc. have?
- About 317 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Wave Life Sciences, Inc.?
- Paul Bolno, MD, MBA, President and Chief Executive Officer at Wave Life Sciences, as named in a 8-K filed October 27, 2026.
- Who is the CFO of Wave Life Sciences, Inc.?
- Kyle Moran, Chief Financial Officer, as named in a 10-K filed February 26, 2026.
- Where is Wave Life Sciences, Inc. headquartered?
- Cambridge, MA.
- What is Wave Life Sciences, Inc.'s stock ticker?
- WVE on Nasdaq.
- What industry is Wave Life Sciences, Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Wave Life Sciences, Inc.'s website?
- wavelifesciences.com.
- When does Wave Life Sciences, Inc. report earnings next?
- November 9, 2026. Source: pg_future_events.
- Is Wave Life Sciences, Inc. a public company?
- Yes. Wave Life Sciences, Inc. files with the SEC under CIK 0001631574 and trades as WVE.
- Who audits Wave Life Sciences, Inc.?
- Kpmg LLP, Boston, Massachusetts, as named in its latest annual report (10-K).
- How many shares of Wave Life Sciences, Inc. are outstanding?
- 197.2 million shares as of October 21, 2026, from its 10-Q filed October 27, 2026.
- What is Wave Life Sciences, Inc.'s public float?
- $851M as of June 30, 2025, as reported on the cover of its 10-K/A filed April 30, 2026.
- How many business segments does Wave Life Sciences, Inc. report?
- 1 reportable segment for the period ending June 30, 2026, from its 10-Q filed July 30, 2026.
- When is Wave Life Sciences, Inc.'s annual shareholder meeting?
- November 12, 2026, per its proxy statement (DEF 14A) filed October 14, 2026.
- Have Wave Life Sciences, Inc. insiders traded stock recently?
- Since August 5, 2025, officers and directors reported 25 open-market sales worth about $18.8M and 8 purchases worth about $219M on Forms 4 and 5. The most recent: Adrian Rawcliffe (Director) sold 12,700 shares on August 12, 2026.